M 011
Alternative Names: GBAM6P; M-011Latest Information Update: 09 Feb 2023
Price :
$50 *
At a glance
- Originator M6P Therapeutics
- Class Enzymes; Recombinant proteins
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gaucher's disease
Most Recent Events
- 09 Feb 2023 M6P Therapeutics plans to submit IND in Gaucher's disease by Q1 2023 (M6P Therapeutics website, February 2023)
- 10 Feb 2022 Pharmacodynamics data from preclinical trial presented at the 18th Annual WORLDSymposium™ (Annual WORLDSymposium-2022)
- 19 Jul 2021 M6P Therapeutics plans a clinical trial for Gaucher's disease in 2022